Cover Image
市場調查報告書

全球新一代抗體治療市場預測:2017年∼2027年

Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs)

出版商 Visiongain Ltd 商品編碼 261354
出版日期 內容資訊 英文 249 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球新一代抗體治療市場預測:2017年∼2027年 Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs)
出版日期: 2017年05月25日 內容資訊: 英文 249 Pages
簡介

一般認為全球新一代抗體治療市場,將從2016年的31億美元,擴大到2021年的141億美元。市場在2016年∼2027年這段期間將以年複合成長率 (CAGR) 22.4%的速度成長。

本報告提供全球新一代抗體治療市場相關調查分析,提供概要,全球/各地區市場,市場預測和開發平台相關的系統性資訊。

第1章 報告概要

第2章 所謂新一代抗體治療

  • 抗體:概要
  • 新一代抗體定義
  • 新一代抗體治療的分類
  • 新一代抗體技術的必要性
  • 新一代抗體的發展趨勢
  • 調查範圍
  • 臨床實驗的階段

第3章 新一代抗體治療:全球市場

  • 全球新一代抗體治療市場概要和區分
  • 主要的新一代抗體治療
  • 全球新一代抗體治療市場:銷售額預測
  • 各種類的市場佔有率的變化預測
  • 全球新一代抗體治療市場:推動因素·阻礙因素

第4章 主要地區市場

  • 全球新一代抗體治療市場地區明細
  • 全球新一代抗體治療市場:不同地區的預測
  • 各地區的市場佔有率的變化預測
  • 美國的新一代抗體治療市場
  • EU5個國家的新一代抗體治療市場
  • 亞太地區的新一代抗體治療市場
  • 南美的新一代抗體治療市場
  • 其他地區的新一代抗體治療市場

第5章 抗體藥物複合體 (ADC) :市場預測和開發平台

  • 市場概要
  • 主要的ADC
  • ADC:市場預測
  • ADC市場:推動因素·阻礙因素
  • Adcetris (brentuximab vedotin,Seattle Genetics/武田藥品工業)
  • Kadcyla (trastuzumab emtansine,Roche)
  • Mylotarg (gemtuzumab ozogamicin,Pfizer)
  • ADC的平台
  • ADC富有魅力的高價交易
  • ADC:開發平台分析
  • ADC:第三階段開發平台
  • ADC:第二階段開發平台
  • ADC:第一階段開發平台
  • ADC:前臨床開發平台
  • ADC技術的未來發展

第6章 基因工程抗體:市場預測和開發平台

  • 「基因工程抗體」定義
  • 市場概要,主要的基因工程抗體
  • 主要的基因工程抗體:市場預測
  • 基因工程抗體市場:推動因素·阻礙因素
  • Poteligeo (mogamulizumab,Kyowa Hakko Kirin)
  • Gazyva/Gazyvaro (obinutuzumab,Roche)
  • 基因工程抗體的平台
  • 基因工程抗體:開發平台分析
  • 基因工程抗體:第三階段開發平台
  • 基因工程抗體:第二階段開發平台
  • 基因工程抗體:第一階段開發平台

第7章 雙特異性抗體:市場預測和開發平台

  • 雙特異性抗體:市場概要
  • 雙特異性抗體:市場預測
  • 雙特異性抗體市場:推動因素·阻礙因素
  • Removab (catumaxomab,Neopharm)
  • Blincyto (blinatumomab,Amgen)
  • 雙特異性抗體的平台
  • 雙特異性抗體:開發平台分析
  • 雙特異性抗體:第一階段·第1/2階段·前臨床開發平台

第8章 抗體片段·抗體樣蛋白質 (ALP) :市場預測和開發平台

  • 抗體片段·ALP:市場概要
  • 抗體片段·ALP:市場預測
  • 抗體片段·ALP:推動因素·阻礙因素
  • Kalbitor (ecallantide,Shire)
  • 抗體片段·ALP的平台
  • 抗體片段·ALP:開發平台分析
  • 抗體片段·ALP:第三階段開發平台
  • 抗體片段·ALP:第二階段開發平台
  • 抗體片段·ALP:第一階段開發平台

第9章 生物相似藥抗體:市場預測

  • 生物相似藥抗體:市場概要
  • 主要的生物相似藥抗體
  • 生物相似藥抗體:市場預測
  • 生物相似藥抗體市場:推動因素·阻礙因素

第10章 新一代抗體治療市場定性分析

  • 新一代抗體治療市場SWOT分析
  • 新一代抗體治療市場STEP分析
  • 新一代抗體開發主要的目標

第11章 結論

第12章 詞彙表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0195

The global next-generation antibody therapies market is expected to grow at a CAGR of 35.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 22.4% from 2016-2027. The market is estimated at $3.1bn in 2016 and $14.1bn in 2021.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 249-page report you will receive 133 charts - all unavailable elsewhere.

The 249-page report provides clear detailed insight into the global next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Next-Generation Antibody Therapies Market forecasts from 2017-2027
  • Along with revenue prediction for the overall world market for next-generation antibody therapies, our investigation shows forecasts to 2027 for the following five submarkets:
    • Antibody-drug conjugates (ADCs)
    • Engineered antibodies
    • Bispecific antibodies
    • Antibody fragments and antibody-like proteins (ALPs)
    • Biosimilar antibody therapies
  • How will leading next-generation antibody therapies perform to 2027 at world level? Our study forecasts individual revenues of seven products:
    • Adcetris
    • Kadcyla
    • Gazyva/Gazyvaro
    • Poteligeo
    • Removab
    • Blincyto
    • Kalbitor
  • Our analyses show individual revenue forecasts to 2027 for these regional markets:
    • US
    • EU5 group
    • Asia-Pacific region
    • Latin America
    • Rest of the World
  • This report discusses issues affecting the next-generation antibody therapies market:
    • R&D for next generation antibodies
    • explore technologies and potentials
    • Challenges with current monoclonal antibody (mAb) therapies
    • Big pharma companies investing in next-generation antibody research and development
    • Biosimilars and their effects on the next-generation antibody therapies market
  • Our study discusses strengths, weaknesses, opportunities and threats as well as social, technological, economic and political factors that affect the next-generation antibody therapies market

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs).

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Next-Generation Antibody Therapies Overview
  • 1.2. Global Next-Generation Antibody Therapies Market Segmentation
  • 1.3. Why you Should Read this Report
  • 1.4. How this Report Delivers
  • 1.5. Main Questions Answered by This Analytical Study
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. Introduction to Next-Generation Antibody Therapies

  • 2.1. Antibodies: An Overview
    • 2.1.1. Monoclonal versus Polyclonal Antibodies
    • 2.1.2. A Brief History of Antibody Drug Development
    • 2.1.3. The Antibody Manufacturing Process
    • 2.1.4. Trends in Antibody Development
  • 2.2. Defining Next-Generation Antibodies
  • 2.3. Classification of Next-Generation Antibody Therapies
  • 2.4. The Need for Next-Generation Technologies
  • 2.5. Development Trends for Next-Generation Antibodies
  • 2.6. Scope of this Report
  • 2.7. Phases of Clinical Trials

3. Next-Generation Antibody Therapies: World Market 2016-2027

  • 3.1. The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2016
  • 3.2. Leading Next-Generation Antibody Therapies
  • 3.3. World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2027
  • 3.4. How Will Segmental Market Shares Change to 2027?
  • 3.5. World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2027

4. Leading Regional Markets 2016-2027

  • 4.1. Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2016
  • 4.2. World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2027
  • 4.3. How Will Regional Market Shares Change to 2027?
  • 4.4. US Next-Generation Antibody Therapies Market 2016-2027
  • 4.5. EU5. Next-Generation Antibody Therapies Market 2016-2027
  • 4.6. Asia-Pacific Next-Generation Antibody Therapies Market 2016-2027
  • 4.7. Latin American Next-Generation Antibody Therapies Market 2016-2027
  • 4.8. The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2027

5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2027

  • 5.1. Market Overview, 2017
  • 5.2. Leading ADCs in 2017
  • 5.3. Antibody-Drug Conjugates: Market Forecast 2016-2027
  • 5.4. The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2027
    • 5.4.1. Novel Approaches Will Drive ADCs Market Growth
    • 5.4.2. Competition for Leading Drugs Will Restrain Growth
    • 5.4.3. Manufacturing ADCs Forms a Challenge
  • 5.5. Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)
    • 5.5.1. Adcetris: Sales 2011-2016
    • 5.5.2. Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
    • 5.5.3. Expanding Adcetris Indications for Future Revenue Growth
    • 5.5.4. Adcetris Sales Forecast 2016-2027
  • 5.6. Kadcyla (trastuzumab emtansine, Roche)
    • 5.6.1. Mixed Results from Different Clinical Trials
    • 5.6.2. NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
    • 5.6.3. Kadcyla Sales Forecast 2016-2027
  • 5.7. Mylotarg (gemtuzumab ozogamicin, Pfizer)
    • 5.7.1. Mylotarg to be Relaunched?
  • 5.8. Antibody-Drug Conjugate Platforms
    • 5.8.1. Limited Market Opportunity for Radioconjugation
    • 5.8.2. Seattle Genetics' Platform Accounted for Over 40% of the Pipeline in 2016
    • 5.8.3. ImmunoGen: TAP Technology
    • 5.8.4. Immunomedics: Lower Potency Cytotoxics for Extended Use
    • 5.8.5. Preclinical Platforms for ADC Development
  • 5.9. ADCs Have Attracted High-Value Deals and will Continue to do so
  • 5.10. Antibody-Drug Conjugates: Pipeline Analysis 2016-2027
    • 5.10.1. The Longest Pipeline in the Next-Generation Antibodies Market
    • 5.10.2. Cancer Is the Only Target for Current Clinical-Stage ADCs
  • 5.11. Antibody-Drug Conjugates: Phase 3 Pipeline
    • 5.11.1. CMC544 (inotuzumab ozogamicin, Pfizer)
    • 5.11.2. Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
  • 5.12. Antibody-Drug Conjugates: Phase 2 Pipeline
    • 5.12.1. ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
    • 5.12.2. BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
    • 5.12.3. CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
    • 5.12.4. Immunomedics' IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
    • 5.12.5. MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
    • 5.12.6. MM-302 (anti-HER2, Merrimack Pharmaceuticals)
    • 5.12.7. PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
    • 5.12.8. SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
    • 5.12.9. Seattle Genetics' Phase 1 and Phase 2 ADCs
  • 5.13. Antibody-Drug Conjugates: Phase 1 Pipeline
  • 5.14. Antibody-Drug Conjugates: Preclinical Pipeline
  • 5.15. Future Developments in ADC Technology
    • 5.15.1. Site-Specific Linkage for Improved Safety Profiles

6. Engineered Antibodies: Market Forecast and Pipeline 2016-2027

  • 6.1. Defining an ‘Engineered Antibody'
  • 6.2. Market Overview 2017, and the Leading Engineered Antibodies
  • 6.3. Leading Engineered Antibodies: Market Forecast 2016-2027
  • 6.4. The Engineered Antibodies Market: Drivers and Restraints 2016-2027
  • 6.5. Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
    • 6.5.1. Poteligeo Sales Forecast 2016-2027
  • 6.6. Gazyva / Gazyvaro (obinutuzumab, Roche)
    • 6.6.1. Gazyva as a Challenger in the anti-CD20 Market
    • 6.6.2. Competition beyond Rituxan and Biosimilars
    • 6.6.3. Gazyva Receives Second Approval
    • 6.6.4. Gazyva Sales Forecast 2016-2027
  • 6.7. Engineered Antibodies Platforms
    • 6.7.1. Roche Glycart: GlucoMAb - Glycosylation for Improved ADCC
    • 6.7.2. Kyowa Hakko Kirin: Potelligent - Enhancing ADCC
    • 6.7.3. Glycotope: GlycoExpress
    • 6.7.4. MacroGenics: Fc Optimization
    • 6.7.5. Xencor: XmAb - Modifying Amino Acids in the Fc Domain
    • 6.7.6. Other Platforms for Increased Potency
  • 6.8. Engineered Antibodies: Pipeline Analysis 2016-2027
  • 6.9. Engineered Antibodies: Phase 3 Pipeline
    • 6.9.1. Benralizumab (MedImmune / Kyowa Hakko Kirin)
    • 6.9.2. Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
    • 6.9.3. MEDI4736 (anti-PDL1, AstraZeneca)
    • 6.9.4. RG7446/MPDL3280A (anti-PDL1, Roche)
    • 6.9.5. Ublituximab (anti-CD20, TG Therapeutics)
  • 6.10. Engineered Antibodies: Phase 2 Pipeline
    • 6.10.1. Glycotope's CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
    • 6.10.2. Margetuximab (anti-HER2, MacroGenics)
    • 6.10.3. MEDI-551 (anti-CD19, AstraZeneca)
    • 6.10.4. MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
    • 6.10.5. Teplizumab (anti-CD3, MacroGenics)
    • 6.10.6. BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
    • 6.10.7. XmAb5871 (anti-CD19, Xencor)
  • 6.11. Engineered Antibodies: Phase 1 Pipeline

7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2027

  • 7.1. Bispecific Antibodies: Market Overview, 2017
  • 7.2. Bispecific Antibodies: Market Forecast 2016-2027
  • 7.3. The Bispecific Antibodies Market: Drivers and Restraints 2016-2027
  • 7.4. Removab (catumaxomab, Neopharm)
    • 7.4.1. Removab: Sales Forecast 2016-2027
  • 7.5. Blincyto (blinatumomab, Amgen)
    • 7.5.1. Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto
    • 7.5.2. Blincyto: Sales Forecast 2016-2027
  • 7.6. Bispecific Antibodies Platforms
    • 7.6.1. BiTE Platform: The Current Market Leader
    • 7.6.2. MacroGenics' DART Platform Holds Promise
    • 7.6.3. TriomAbs (TRION Pharma): Limited Market Impact 2016-2027
    • 7.6.4. Other Bispecific Antibody Platforms
  • 7.7. Bispecific Antibodies: Pipeline Analysis 2016-2027
    • 7.7.1. Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
    • 7.7.2. ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
    • 7.7.3. AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
    • 7.7.4. MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
    • 7.7.5. MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
    • 7.7.6. SAR156597 (anti-IL-4 and IL-13, Sanofi)
    • 7.7.7. Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
  • 7.8. Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline

8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2027

  • 8.1. Antibody Fragments and ALPs: Market Overview, 2017
  • 8.2. Antibody Fragments and ALPs: Market Forecast 2016-2027
  • 8.3. The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2027
  • 8.4. Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio
    • 8.4.1. Kalbitor: Sales Forecast 2016-2027
  • 8.5. Antibody Fragments and ALPs Platforms
    • 8.5.1. Single-chain Variable Fragment Platforms
    • 8.5.2. Non-Antibody Protein Scaffolds: Antibody-Like Proteins
    • 8.5.3. Which Platform Will Lead the Market 2016-2027?
  • 8.6. Antibody Fragments and ALPs: Pipeline Analysis 2016-2027
    • 8.6.1. Ablynx Leads the Pipeline with Six Clinical Projects
  • 8.7. Antibody Fragments and ALPs: Phase 3 Pipeline
    • 8.7.1. Caplacizumab (anti-vWF, Ablynx)
    • 8.7.2. Abicipar (anti-VEGF, Allergan/Molecular Partners)
  • 8.8. Antibody Fragments and ALPs: Phase 2 Pipeline
    • 8.8.1. ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
    • 8.8.2. Ozoralizumab (anti-TNFα, Ablynx )
    • 8.8.3. DLX105 (anti-TNF-α, Delenex Therapeutics)
    • 8.8.4. ESBA1008 (anti-VEGF, Novartis)
  • 8.9. Antibody Fragments and ALPs: Phase 1 Pipeline
    • 8.9.1. ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
    • 8.9.2. ALX-0171 (anti-respiratory syncytial virus)
    • 8.9.3. ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
    • 8.9.4. Other Phase 1 Candidates, and the Preclinical Pipeline

9. Biosimilar Antibodies: Market Forecast 2016-2027

  • 9.1. Biosimilar Antibodies: Market Overview, 2017
  • 9.2. Leading Biosimilar Antibodies in 2016.
  • 9.3. Biosimilar Antibodies: Market Forecast 2016-2027
  • 9.4. The Biosimilar Antibodies Market: Drivers and Restraints 2016-2027
    • 9.4.1. New Launches of Biosimilar mAbs in Developed and Emerging Markets
    • 9.4.2. Rising Incidence of Cancer will Drive Demand
    • 9.4.3. Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
    • 9.4.4. Will Biosimilars Challenge Next-Generation Antibodies in this Decade?

10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2027

  • 10.1. SWOT Analysis of the Next-Generation Antibody Therapies Market
    • 10.1.1. Strengths: The Path Towards Market Acceptance
    • 10.1.2. Weaknesses: Multiple Companies Targeting Similar Indications
    • 10.1.3. Opportunities: Novel Platforms
    • 10.1.4. Threats: Entry of Biosimilars
  • 10.2. STEP Analysis of the Next-Generation Antibody Therapies Market
    • 10.2.1. Social Factors: Rising Demand for Cancer Therapies
    • 10.2.2. Technological Developments Will Drive Pipeline Growth
    • 10.2.3. Economic Pressures
    • 10.2.4. Political and Regulatory Issues
  • 10.3. Key Targets for Next-Generation Antibody Development 2016-2027
    • 10.3.1. Oncology Is the Lead Indication in All Sectors

11. Conclusions

  • 11.1. High Growth Potential in the Next-Generation Antibody Therapies Market in 2016-2027
  • 11.2. Current Status of the Market and Leading Segments
  • 11.3. Leading Next-Generation Antibody Therapies Profiled in this Report
  • 11.4. Leading Regional Markets
  • 11.5. Development of the Market to 2027
  • 11.6. Technology Platforms Will Continue to Attract Big Pharma Interest
  • 11.7. Most Developers Continue to Target Cancer
  • 11.8. Strategies for Growth in 2016-2027

12. Glossary

  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 1.1 (Sample) World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2016-2021
  • Table 2.1 Monoclonal Antibody Types and Sources, 2017
  • Table 2.2 The Different Phases of Clinical Trials and What They Assess
  • Table 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2016
  • Table 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2016-2021
  • Table 3.3 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2022-2027
  • Table 3.4 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2027
  • Table 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2016
  • Table 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2016-2021
  • Table 4.3 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2022-2027
  • Table 4.4 Revenue ($m) and Market Shares (%) of Leading Regional Next-Generation Antibody Therapies Markets, 2027
  • Table 4.5 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.6 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 4.7 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.8 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 4.9 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.10 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 4.11 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.12 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 4.13 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.14 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 5.1 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2016-2021
  • Table 5.2 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2022-2027
  • Table 5.3 Seattle Genetics: Adcetris Revenue ($m), 2011-2016
  • Table 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m), 2013-2016
  • Table 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 5.6 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 5.7 Kadcyla Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 5.8 Kadcyla Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 5.9 ADC Pipeline by Platform and Phase, 2016
  • Table 5.10 Selected Preclinical ADC Development Platforms, 2016
  • Table 5.11 ADC Pipeline by Indication and Phase, 2016
  • Table 5.12 ADC Pipeline by Indication and Phase 3, 2016
  • Table 5.13 Selected Ongoing Clinical Trials for CMC544 (inotuzumab ozogamicin), 2016
  • Table 5.14 Roche's Antibody-Drug Conjugates Pipeline, 2016
  • Table 5.15 Ongoing Clinical Trials for RG7596 (polatuzumab vedotin), 2016
  • Table 5.16 Antibody-Drug Conjugates: Phase 2 Pipeline, 2016
  • Table 5.17 Ongoing Clinical Trials for ABT-414, 2016
  • Table 5.18 Antibody-Drug Conjugates: Phase 1 Pipeline, Table 1, 2015 and 2016
  • Table 5.19 Antibody-Drug Conjugates: Phase 1 Pipeline, Table 2, 2016
  • Table 5.20 Antibody-Drug Conjugates: Preclinical Pipeline, 2016
  • Table 6.1 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021
  • Table 6.2 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027
  • Table 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 6.4 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 6.5 Total Gazyva Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 6.6 Total Gazyva Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 6.7 Engineered Antibodies Pipeline by Company and Phase, 2016
  • Table 6.8 Selected Licensing Agreements for the Potelligent Platform and Cell Lines, 2008-2015
  • Table 6.9 Engineered Antibodies Pipeline by Indication and Phase, 2016
  • Table 6.10 Engineered Antibodies: Phase 3 Pipeline, 2016
  • Table 6.11 Engineered Antibodies: Phase 2 Pipeline, 2016
  • Table 6.12 Margetuximab Recent and Ongoing Clinical Trials, 2016
  • Table 6.13 MEDI-551 Recent and Ongoing Clinical Trials, 2016
  • Table 6.14 Engineered Antibodies: Phase 1 Pipeline, 2016
  • Table 7.1 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021
  • Table 7.2 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027
  • Table 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 7.4 Removab (Neopharm) Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 7.5 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 7.6 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 7.7 Bispecific Antibodies Pipeline by Company and Phase, 2016
  • Table 7.8 Selected Preclinical Bispecific Antibody Platforms, 2016
  • Table 7.9 Bispecific Antibodies Pipeline by Indication and Phase, 2016
  • Table 7.10 Bispecific Antibodies Pipeline by Indication and Phase, 2016
  • Table 7.11 Bispecific Antibodies: Phase 1/2 Pipeline, 2016, Table 1
  • Table 7.12 Bispecific Antibodies: Phase 1 Pipeline, 2016, Table 2
  • Table 7.13 Bispecific Antibodies: Preclinical Pipeline, 2016
  • Table 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021
  • Table 8.2 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027
  • Table 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 8.4 Kalbitor Revenue Forecast (Shire): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 8.5 Ablynx: Selected Big Pharma Collaboration Agreements, 2012-2015
  • Table 8.6 Antibody Fragments and ALPs Pipeline by Company and Phase, 2016
  • Table 8.7 Antibody Fragments and ALPs Pipeline by Indication and Phase, 2016
  • Table 8.8 Antibody Fragments and ALPs: Phase 1 Pipeline, 2016
  • Table 8.9 Antibody Fragments and ALPs: Preclinical Pipeline, 2016
  • Table 9.1 Top Ten Best-Selling Drugs of 2014 (Within the Overall Pharmaceutical Market): Revenues ($bn), Market Shares (%)
  • Table 9.2 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 9.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 9.4 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 9.5 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 9.6 Patent Status of Five Leading mAbs, 2016
  • Table 10.1 Next-Generation Antibody Therapies Market: STEP Analysis, 2016-2027
  • Table 10.2 Selected CMOs Investing in Next-Generation Antibody Technologies, 2005-2015
  • Table 10.3 HER2 and HER3-Targeting Next-Generation Antibodies: Pipeline, 2016
  • Table 10.4 CD19 and CD20-Targeting Next-Generation Antibodies: Pipeline, 2016

List of Figures

  • Figure 1.1 Global Next-Generation Antibody Therapies Market Segmentation Overview, 2017
  • Figure 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2016
  • Figure 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%) by Segment, 2016-2027
  • Figure 3.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2027
  • Figure 3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints, 2016-2027
  • Figure 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) by Region, 2016
  • Figure 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m) by Region, 2016-2027
  • Figure 4.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Region, 2027
  • Figure 4.4 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.5 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.6 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.7 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.8 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.1 ADC Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.2 ADC Market: Drivers and Restraints, 2016-2027
  • Figure 5.3 Seattle Genetics: Adcetris Revenue ($m) and AGR (%), 2011-2016
  • Figure 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m) and AGR (%), 2013-2016
  • Figure 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.6 Kadcyla Revenue Forecast (Roche): Revenue ($m), 2016-2027
  • Figure 5.7 ADC Pipeline by Platform, 2016
  • Figure 5.8 ADC Pipeline by Phase, 2016
  • Figure 5.9 ADC Pipeline by Indication, 2016
  • Figure 6.1 Engineered Antibodies Market Forecast: Revenues ($m), 2016-2027
  • Figure 6.2 Engineered Antibodies Market: Drivers and Restraints, 2016-2027
  • Figure 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), 2016-2027
  • Figure 6.4 Total Gazyva Revenue Forecast (Roche): Revenue ($m), 2016-2027
  • Figure 6.5 Engineered Antibodies Pipeline by Company, 2016
  • Figure 6.6 Engineered Antibodies Pipeline by Indication, 2016
  • Figure 6.7 Engineered Antibodies Pipeline by Phase, 2016
  • Figure 7.1 Bispecific Antibodies Market: Drivers and Restraints, 2016-2027
  • Figure 7.2 Bispecific Antibodies Market Forecast: Revenue ($m), 2016-2027
  • Figure 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), 2016-2027
  • Figure 7.4 Blincyto Revenue Forecast (Amgen): Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.5 Bispecific Antibodies Pipeline by Company, 2016
  • Figure 7.6 Bispecific Antibodies Pipeline by Indication, 2016
  • Figure 7.7 Bispecific Antibodies Pipeline by Phase, 2016
  • Figure 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), 2016-2027
  • Figure 8.2 Antibody Fragments and ALPs Market: Drivers and Restraints, 2016-2027
  • Figure 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.4 Antibody Fragments and ALPs Pipeline by Company, 2016
  • Figure 8.5 Antibody Fragments and ALPs Pipeline by Indication, 2016
  • Figure 8.6 Antibody Fragments and ALPs Pipeline by Phase, 2016
  • Figure 9.1 Biosimilar Monoclonal Antibody Market Forecast, Split by Product: Revenue ($bn), 2016-2027
  • Figure 9.2 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn) and AGR(%), 2016-2027
  • Figure 10.1 Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2016-2027
  • Figure 10.2 Next-Generation Antibody Therapies Market: Opportunities and Threats, 2016-2026

Companies Listed

  • AbbVie
  • Ablynx
  • AdAlta
  • ADC Therapeutics
  • Affimed Therapeutics
  • Agensys
  • Alcon
  • Alexion
  • Allergan
  • Ambrx
  • Amgen
  • arGEN-X
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen Idec
  • BioNet Ventures
  • Biotest
  • BioWa
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cancer Drugs Fund
  • Catalent Pharma Solutions
  • Celgene
  • Celldex Therapeutics
  • Cephalon
  • Cilag GmbH International
  • Coldstream Laboratories
  • Concortis Biosystems
  • Corixa
  • Covagen
  • Crescendo Biologics
  • CSL Behring
  • CVie Therapeutics
  • Daiichi Sankyo
  • Defiante Farmaceutica
  • Delenex Therapeutics
  • Domantis
  • Dutalys
  • Dyax
  • Eddingpharm
  • Eisai
  • Eli Lilly
  • ESBATech
  • FDA
  • Five Prime Therapeutics
  • Fresenius Biotech
  • F-Star
  • Fujifilm
  • Genentech
  • Genmab
  • Gilead Sciences
  • Glenmark
  • Glycotope
  • Goodwin Biotechnology
  • GSK
  • Igenica
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • Janssen Biotech
  • Kalobios
  • Karolinska Institute
  • Kyowa Hakko Kirin
  • Kyowa Medex
  • LINDIS Biotech
  • Lonza
  • MacroGenics
  • MedImmune
  • Merck
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Micromet
  • Millennium Pharmaceuticals
  • Molecular Partners
  • MorphoSys
  • MultiCell Immunotherapeutics (MCIT)
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Neopharm
  • Neovii Biotech
  • NHS
  • NICE
  • Novartis
  • Novartis Institutes for BioMedical Research (NIBR)
  • NovImmune
  • Oxford BioTherapeutics
  • Oxis
  • Pfizer
  • Pharmacyclics
  • Piramal Healthcare
  • Pieris
  • Piramal Enterprises
  • PolyTherics
  • Progenics
  • ProStrakan
  • Redwood BioScience
  • Roche
  • Salix
  • Sanofi
  • Scil Proteins
  • Seattle Genetics
  • Servier
  • Shinogi
  • Shire
  • Sigma-Tau
  • Sorrento Therapeutics
  • Spectrum Pharmaceuticals
  • Spirogen
  • Stelis Biopharma
  • Strides Arcolab
  • Sutro Biopharma
  • Swedish Orphan Biovitrum (Sobi)
  • Swiss Federal Institute of Technology
  • Synthon
  • Takeda
  • Talon Therapeutics
  • Teva
  • TG Therapeutics
  • The American Society of Hematology
  • TRION Pharma
  • UCB
  • WHO
  • Wyeth
  • Xencor
  • Zydus Cadila
Back to Top